The Puerto Rico Health Insurance Administration (ASES) has signed an agreement with miR Scientific to evaluate the economic and health benefits of using the miR Sentinel PCC4 Assay, also called the miR Sentinel Prostate Test, to alleviate the burden of prostate cancer in the U.S. territory. Prostate cancer is the most common form of cancer and the most common cause of cancer death among men in Puerto Rico, prompting ASES to consider new ways of combatting…
You must be logged in to read/download the full post.
The post Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers appeared first on BioNewsFeeds.